Medifast

MED

Market cap $128M

MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss.

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Fiel.

MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss.

MED witnesses revenue plunge as its coach base shrank, but restructuring and productivity initiatives aim to stabilize results by late 2025.

MED targets long-term metabolic health with programs that preserve muscle and support lasting wellness amid GLP-1 adoption.

BALTIMORE--(BUSINESS WIRE)--OPTAVIA, the science-backed, coach-guided lifestyle system, announced a new report “Metabolic Health in America: Awareness, Attitudes and Action.” The report includes findings based on an online survey conducted by OPTAVIA with KRC Research among a nationally representative group of U.S. adults ages 18–75, recruited to match U.S. Census demographics*. The data highlights a pressing concern: 80% of American adults lack understanding of metabolic health, yet many are e.

BALTIMORE--(BUSINESS WIRE)--Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by unveiling new research findings during ObesityWeek. Hosted by The Obesity Society in Atlanta, Georgia November 4–7, 2025, the annual conference for obesity researchers and clinicians centers on the latest developments in evidence-based obesity science: cutting-edge basic.

MED's third-quarter results reflect pressure from fewer active OPTAVIA Coaches, but it is steering toward metabolic health for growth.

Medifast, Inc. ( MED ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Steven Zenker - Vice President of Investor Relations Daniel Chard - Executive Chairman & CEO James Maloney - Chief Financial Officer Nicholas Johnson - Chief Field Operations Officer Conference Call Participants James Salera - Stephens Inc., Research Division Presentation Operator Greetings, and welcome to the Medifast Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTAVIA® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and i.